Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

CervoMed (CRVO) Shares Outstanding (Diluted Average) (2022 - 2024)

CervoMed (CRVO) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $8.7 million as the latest value for Q3 2024.

  • Quarterly Shares Outstanding (Diluted Average) rose 131.04% to $8.7 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $8.7 million through Sep 2024, up 131.04% year-over-year, with the annual reading at $2.6 million for FY2013, 135.89% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $8.7 million in Q3 2024 for CervoMed, up from $3.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $8.7 million in Q3 2024 to a low of $518140.0 in Q3 2022.
  • Historically, Shares Outstanding (Diluted Average) has averaged $4.3 million across 3 years, with a median of $3.8 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): surged 626.97% in 2023 and later surged 131.04% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $518140.0 in 2022, then soared by 626.97% to $3.8 million in 2023, then skyrocketed by 131.04% to $8.7 million in 2024.
  • Business Quant data shows Shares Outstanding (Diluted Average) for CRVO at $8.7 million in Q3 2024, $3.8 million in Q3 2023, and $518140.0 in Q3 2022.